SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Spekulatius who wrote (38277)6/12/2010 11:01:28 AM
From: E_K_S  Read Replies (2) of 78751
 
Hi Spekulatius

RE: LIFE, BDX, VAR & Applied Bio Systems

In the late 80's I invested in a theme of companies that designed, built, serviced and supplied the biotech industry test equipment and consumables for genetic research. One of the companies I owned was Applied Bio Systems ( en.wikipedia.org )which was later acquired by Perkin Elmer then merged with Invitrogen to create a global biotech company called Life Technologies (Life Technologies Corporation (LIFE). What attracted me to this sector was the huge cash flow generated from the consumable reagents sold that were use in their DNA sequencing equipment.

Both Varian Medical Systems Inc. (VAR) (formerly known as Varian Associates, Inc.) and Becton, Dickinson and Company (BDX) were companies I followed. When my Applied Bio Systems was bought out, I stopped following the group and moved on to other investment themes.

It's interesting to note that the survivors VAR & BDX have little debt, continue to generate excellent cash flows and have grown to be global companies. Many of the companies like (Life Technologies Corporation (LIFE) carry a lot of goodwill on their books representing the collection of companies acquired over this period. They also have accumulated lots of debt too. In the case of LIFE they have more than 8x the debt load relative to their annual revenues than BDX.

I wonder if it time to search out the past legacy innovators that have remained independent, have grown and developed their business and are ripe "value buys" that have little debt. The management style for these types of companies show that they are survivors, are not interested in being acquired, are in the business for the long hall and deliver growth and shareholder value year after year.

I am more convinced now that BDX is one of these companies as I reflect back on my basket of bio-tech stocks that I followed. I think I will investigate further and go "Back To The Future" to see if any other legacy survivors pop up from my old lists.

EKS
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext